PortfoliosLab logo
CPRX vs. ENSG
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between CPRX and ENSG is 0.44, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.


Performance

CPRX vs. ENSG - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Catalyst Pharmaceuticals, Inc. (CPRX) and The Ensign Group, Inc. (ENSG). The values are adjusted to include any dividend payments, if applicable.

Loading data...

Key characteristics

Sharpe Ratio

CPRX:

1.19

ENSG:

0.99

Sortino Ratio

CPRX:

1.95

ENSG:

1.47

Omega Ratio

CPRX:

1.22

ENSG:

1.20

Calmar Ratio

CPRX:

1.65

ENSG:

1.15

Martin Ratio

CPRX:

6.46

ENSG:

2.52

Ulcer Index

CPRX:

7.40%

ENSG:

10.71%

Daily Std Dev

CPRX:

41.35%

ENSG:

26.26%

Max Drawdown

CPRX:

-94.25%

ENSG:

-55.56%

Current Drawdown

CPRX:

-5.32%

ENSG:

-4.47%

Fundamentals

Market Cap

CPRX:

$2.97B

ENSG:

$8.61B

EPS

CPRX:

$1.57

ENSG:

$5.39

PE Ratio

CPRX:

15.52

ENSG:

27.78

PEG Ratio

CPRX:

0.00

ENSG:

1.56

PS Ratio

CPRX:

5.56

ENSG:

1.95

PB Ratio

CPRX:

3.65

ENSG:

4.39

Total Revenue (TTM)

CPRX:

$534.65M

ENSG:

$4.42B

Gross Profit (TTM)

CPRX:

$441.72M

ENSG:

$676.18M

EBITDA (TTM)

CPRX:

$250.28M

ENSG:

$495.95M

Returns By Period

In the year-to-date period, CPRX achieves a 16.77% return, which is significantly higher than ENSG's 12.77% return. Over the past 10 years, CPRX has underperformed ENSG with an annualized return of 19.87%, while ENSG has yielded a comparatively higher 21.84% annualized return.


CPRX

YTD

16.77%

1M

8.21%

6M

18.30%

1Y

47.79%

5Y*

40.03%

10Y*

19.87%

ENSG

YTD

12.77%

1M

17.01%

6M

4.46%

1Y

25.24%

5Y*

29.70%

10Y*

21.84%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

CPRX vs. ENSG — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CPRX
The Risk-Adjusted Performance Rank of CPRX is 8686
Overall Rank
The Sharpe Ratio Rank of CPRX is 8787
Sharpe Ratio Rank
The Sortino Ratio Rank of CPRX is 8585
Sortino Ratio Rank
The Omega Ratio Rank of CPRX is 8080
Omega Ratio Rank
The Calmar Ratio Rank of CPRX is 9191
Calmar Ratio Rank
The Martin Ratio Rank of CPRX is 9090
Martin Ratio Rank

ENSG
The Risk-Adjusted Performance Rank of ENSG is 7979
Overall Rank
The Sharpe Ratio Rank of ENSG is 8383
Sharpe Ratio Rank
The Sortino Ratio Rank of ENSG is 7676
Sortino Ratio Rank
The Omega Ratio Rank of ENSG is 7676
Omega Ratio Rank
The Calmar Ratio Rank of ENSG is 8585
Calmar Ratio Rank
The Martin Ratio Rank of ENSG is 7676
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

CPRX vs. ENSG - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Catalyst Pharmaceuticals, Inc. (CPRX) and The Ensign Group, Inc. (ENSG). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


The current CPRX Sharpe Ratio is 1.19, which is comparable to the ENSG Sharpe Ratio of 0.99. The chart below compares the historical Sharpe Ratios of CPRX and ENSG, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Loading data...

Dividends

CPRX vs. ENSG - Dividend Comparison

CPRX has not paid dividends to shareholders, while ENSG's dividend yield for the trailing twelve months is around 0.16%.


TTM20242023202220212020201920182017201620152014
CPRX
Catalyst Pharmaceuticals, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
ENSG
The Ensign Group, Inc.
0.16%0.18%0.21%0.24%0.25%0.28%0.40%0.47%0.78%0.73%0.97%0.57%

Drawdowns

CPRX vs. ENSG - Drawdown Comparison

The maximum CPRX drawdown since its inception was -94.25%, which is greater than ENSG's maximum drawdown of -55.56%. Use the drawdown chart below to compare losses from any high point for CPRX and ENSG. For additional features, visit the drawdowns tool.


Loading data...

Volatility

CPRX vs. ENSG - Volatility Comparison

Catalyst Pharmaceuticals, Inc. (CPRX) has a higher volatility of 10.00% compared to The Ensign Group, Inc. (ENSG) at 9.16%. This indicates that CPRX's price experiences larger fluctuations and is considered to be riskier than ENSG based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading data...

Financials

CPRX vs. ENSG - Financials Comparison

This section allows you to compare key financial metrics between Catalyst Pharmaceuticals, Inc. and The Ensign Group, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.00200.00M400.00M600.00M800.00M1.00B1.20B20212022202320242025
141.42M
1.17B
(CPRX) Total Revenue
(ENSG) Total Revenue
Values in USD except per share items

CPRX vs. ENSG - Profitability Comparison

The chart below illustrates the profitability comparison between Catalyst Pharmaceuticals, Inc. and The Ensign Group, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

20.0%40.0%60.0%80.0%20212022202320242025
87.3%
16.0%
(CPRX) Gross Margin
(ENSG) Gross Margin
CPRX - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Catalyst Pharmaceuticals, Inc. reported a gross profit of 123.51M and revenue of 141.42M. Therefore, the gross margin over that period was 87.3%.

ENSG - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, The Ensign Group, Inc. reported a gross profit of 188.12M and revenue of 1.17B. Therefore, the gross margin over that period was 16.0%.

CPRX - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Catalyst Pharmaceuticals, Inc. reported an operating income of 63.37M and revenue of 141.42M, resulting in an operating margin of 44.8%.

ENSG - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, The Ensign Group, Inc. reported an operating income of 101.37M and revenue of 1.17B, resulting in an operating margin of 8.6%.

CPRX - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Catalyst Pharmaceuticals, Inc. reported a net income of 56.74M and revenue of 141.42M, resulting in a net margin of 40.1%.

ENSG - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, The Ensign Group, Inc. reported a net income of 80.28M and revenue of 1.17B, resulting in a net margin of 6.8%.